SBP-3264, a recently developed MST1/2 inhibitor, aims to impede the tumourigenesis and progression of various haematological malignancies, such as acute myeloid leukaemia (AML) and multiple myeloma (MM). The gene discussed is MST1; the disease is Miyoshi myopathy.